Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL

Author:

Wierda William G.1,Kipps Thomas J.2,Al-Sawaf Othman3,Chyla Brenda4,Biondo Juliana M. L.5,Mun Yong5,Jiang Yanwen5,Seymour John F.6

Affiliation:

1. University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. UCSD Moores Cancer Center, San Diego, CA, USA

3. Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Düsseldorf, German CLL Study Group, University Hospital, University of Cologne, Cologne, Germany

4. AbbVie Inc., North Chicago, IL, USA

5. Genentech, Inc., South San Francisco, CA, USA

6. Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, VIC, Australia

Funder

F. Hoffmann-La Roche

F. Hoffmann-La Roche Ltd

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. An update on the efficacy of Venetoclax for chronic lymphocytic leukemia;Expert Opinion on Pharmacotherapy;2023-05-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3